Back HIV/AIDS

HIV / AIDS

New Research Sheds Light on Origin of HIV in U.S., Dispelling Patient Zero Myth

A new genetic analysis shows that HIV likely spread from the Caribbean to New York City around 1971 and from there to San Francisco around 1976, laying to rest the misconception that a Canadian flight attendant, Gaetan Dugas, was responsible for sparking the epidemic in the United States.

alt

IDWeek 2016: HIV+ Men and Men on PrEP in Boston See Large Increase in Sexually Transmitted Infections

Rates of gonorrhea, syphilis, and chlamydia have risen steeply at Fenway Health in Boston since 2011, according to presentation last week at IDWeek in New Orleans. Being HIV-positive and using pre-exposure prophylaxis (PrEP) to prevent HIV were associated with higher risk of getting-sexually transmitted infections (STIs), but more frequent STI testing and treatment could potentially help reduce the numbers.

alt

HIVR4P: New HIV Prevention Tools Will Need Marketing and Effective Health Services to Expand Reach

There is a naivety among many HIV prevention researchers and advocates about the steps needed to introduce and implement new HIV prevention technologies such as oral pre-exposure prophylaxis (PrEP), vaginal rings, and vaccines, according to speakers at the HIV Research for Prevention (HIVR4P 2016) conference in Chicago last month. Developing an effective prevention method is the easy part, they suggested -- ensuring that the product reaches end users who need them can be more challenging.

alt

HIV Glasgow: HIV Treatment Benefits Outweigh Clinical Impact of Lipodystrophy

Over a 20-year period, people who suffered lipodystrophy (abnormal fat distribution) and especially lipoatrophy (fat loss) when they started antiretroviral therapy (ART) actually had better health outcomes than people who did not suffer from it, according to a report at the 2016 International Congress on Drug Therapy in HIV Infection (HIV Glasgow) last week.

alt

IDWeek 2016: Dolutegravir Regimen Works Better than Atazanavir in Clinical Trial for Women

A once-daily regimen containing the potent HIV integrase inhibitor dolutegravir worked better than an older atazanavir-containing regimen -- with higher rates of viral suppression both overall and across race subgroups -- in the ARIA trial, one of the few antiretroviral therapy studies to enroll only women, according to a presentation at IDWeek last week in New Orleans.

alt

HIV Glasgow: Tests of Online PrEP Purchases Find No Fakes and Adequate Drug Levels

A sexual health clinic in central London that offered to test drug levels in users of tenofovir/emtricitabine pre-exposure prophylaxis (PrEP) who had bought it online found adequate levels of both drugs in their blood, and no sample suggesting counterfeit drugs.

alt

IDWeek 2016: Do HIV-Positive Men with Undetectable Viral Load Need to Wear Condoms?

In the face of extensive research showing that HIV-positive people on antiretroviral therapy (ART) with stable undetectable viral load have an extremely low likelihood of transmitting the virus, a majority of participants at IDWeek 2016 in New Orleans thought they should still be advised to use condoms -- a proportion that actually increased after a debate that laid out the evidence.

alt